ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ANI PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Ani Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $1.67B | $197.05M |
| Enterprise Value | $1.61B | $106.56M |
| PE Ratio | 15.44 | 20.52 |
| PS Ratio | 1.70 | 3.93 |
| PB Ratio | 2.79 | 2.14 |
| P/TBV Ratio | 19.64 | 2.46 |
| P/FCF Ratio | 9.63 | 18.25 |
| P/OCF Ratio | 8.80 | 13.78 |
Enterprise value
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 1.64 | 2.69 |
| EV / EBITDA | 6.81 | 14.86 |
| EV / EBIT | 10.69 | 19.00 |
| EV / FCF | 9.30 | 21.02 |
Income (trailing twelve months)
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $978.38M | $57.94M |
| Gross Profit | $590.98M | $90.47M |
| Operating Income | $150.36M | -$21.44M |
| Pretax Income | $142.60M | -$14.45M |
| Net Income | $108.31M | -$22.46M |
| EBITDA | $236.16M | -$16.91M |
| EPS (Diluted) | $4.70 | -$0.83 |
Margins
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 60.4% | 52.3% |
| Operating Margin | 15.4% | -44.5% |
| Pretax Margin | 14.6% | -13.0% |
| Profit Margin | 11.1% | -39.2% |
| EBITDA Margin | 24.1% | -31.3% |
| FCF Margin | 17.7% | -8.85% |
Returns
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 21.0% | -53.1% |
| Return on Assets (ROA) | 7.64% | -41.0% |
| Return on Invested Capital (ROIC) | 21.3% | -32.0% |
| Return on Capital Employed (ROCE) | 12.4% | -37.8% |
Growth
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 30.9% | 6.01% |
| FCF Growth (YoY) | 37.9% | 2.34% |
| Revenue Growth (3Y CAGR) | 40.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 33.5% | 6.42% |
Balance sheet
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $360.21M | $62.42M |
| Total Debt | $301.48M | $120.13M |
| Net Cash (Debt) | $58.73M | $15.68M |
| Net Cash Per Share | $2.56 | $0.65 |
| Equity (Book Value) | $597.21M | $48.79M |
| Book Value Per Share | $26.00 | $1.36 |
| Tangible Book Value | $84.88M | $23.06M |
| Working Capital | $541.78M | $75.77M |
Financial position
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.91 | 3.30 |
| Quick Ratio | 2.24 | 2.39 |
| Debt / Equity | 0.50 | 0.51 |
| Debt / EBITDA | 1.28 | 3.35 |
| Debt / FCF | 1.74 | 5.05 |
| Net Debt / EBITDA | -0.25 | 2.22 |
| Interest Coverage | 4.81 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $189.47M | -$12.35M |
| Capital Expenditures | -$16.48M | -$1.06M |
| Free Cash Flow | $172.99M | -$20.28M |
| FCF Per Share | $7.53 | -$0.41 |
Efficiency
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.69 | 0.38 |
| Inventory Turnover | 2.75 | 2.67 |
| Revenue Per Employee | $1.01M | $398.96K |
| Profits Per Employee | $111.66K | -$732.08K |
| Employee Count | 970 | 73 |
Dividends and yields
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 6.50% | -21.2% |
| FCF Yield | 10.4% | -7.64% |
| Buyback Yield | 1.33% | -0.58% |
| Shareholder Yield | 1.33% | 0.00% |
| Payout Ratio | 0.32% | 47.7% |
| FCF Payout Ratio | 0.20% | 51.6% |
Shares
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 22,970,400 | 59,128,900 |
| Shares Change (YoY) | 9.50% | 11.1% |
| Float | 20,146,800 | 48,744,500 |
| Shares Held by Insiders | 12.3% | 11.8% |
| Shares Held by Institutions | 100.1% | 59.4% |
Taxes
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $34.29M | $91.50K |
| Effective Tax Rate | 24.0% | 20.6% |
Scores
| Measure | Ani Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $52.43 | $17.36 |
| Graham Upside | -27.7% | -45.5% |
| Altman Z-Score | 2.57 | 0.10 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -2.64 | -2.62 |
Calculated by StockData from Ani Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.